Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $9.00 Consensus Target Price from Analysts

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) have earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.00.

A number of equities analysts have issued reports on RLMD shares. Leerink Partners upgraded shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 target price for the company in a research report on Friday, January 23rd. Mizuho increased their price target on shares of Relmada Therapeutics from $10.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday. Zacks Research raised shares of Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. Lucid Cap Mkts upgraded Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th.

Key Relmada Therapeutics News

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target sharply to $19 and upgraded RLMD to “Outperform,” implying large upside from current levels — this is a clear buy-side catalyst that can drive buying interest and re-rate sentiment. Read More.
• Positive Sentiment: Company press release highlights audited Q4 and full‑year 2025 results and a corporate update describing “significant progress across its pipeline” (ongoing clinical and strategic milestones). Pipeline advancement tends to support longer-term valuation for clinical-stage biotech. Read More.
• Neutral Sentiment: Earnings call transcripts and highlights from multiple outlets provide management commentary on strategy, program timelines and cash runway; useful for investors parsing catalysts but not an immediate market mover on their own. Review the call transcript for details on enrollment, milestones and guidance. Read More.
• Negative Sentiment: Relmada reported Q4 EPS of ($0.27), missing consensus (~($0.14)) by ~$0.13 — a near-term negative that highlights continued operating losses and may pressure sentiment until clearer revenue or milestone offsets emerge. Read More.

Relmada Therapeutics Stock Down 2.9%

Shares of RLMD stock opened at $6.07 on Friday. The stock has a market cap of $445.11 million, a P/E ratio of -4.19 and a beta of 0.72. Relmada Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $7.51. The business has a fifty day simple moving average of $4.50 and a 200-day simple moving average of $3.59.

Relmada Therapeutics (NASDAQ:RLMD) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.13). On average, sell-side analysts anticipate that Relmada Therapeutics will post -2.73 earnings per share for the current year.

Institutional Trading of Relmada Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of Relmada Therapeutics during the second quarter valued at $28,000. Goldman Sachs Group Inc. acquired a new position in Relmada Therapeutics in the 1st quarter valued at about $33,000. LMR Partners LLP purchased a new position in Relmada Therapeutics in the 2nd quarter valued at about $33,000. Schonfeld Strategic Advisors LLC purchased a new position in Relmada Therapeutics in the 4th quarter valued at about $64,000. Finally, Jane Street Group LLC acquired a new stake in shares of Relmada Therapeutics during the 2nd quarter worth about $69,000. 45.24% of the stock is currently owned by hedge funds and other institutional investors.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.